(CercleFinance.com) – AB Science announces today that it has received a notice of deficiency (NOD) from Health Canada, as part of the marketing application for masitinib in the treatment of amyotrophic lateral sclerosis.
This NOD means that Health Canada has requested that additional information be shared as part of the masitinib marketing application.
The review process has been paused and will resume when this information has been communicated to Health Canada.
AB Science will therefore approach Health Canada in order to respond to the agency’s objections, with the intention of resuming the file review process within the time allowed.